Table 2.
Characteristics of Study Sample During a Period Dominated by the Delta Variant (1 July to 12 December 2021)a
| Study Participants, No. (Column %) | ||||||||
|---|---|---|---|---|---|---|---|---|
| BNT162b2 Vaccine | mRNA1273 Vaccine | |||||||
| Characteristic | Total | Unvaccinated | 2 Doses | 3 Doses | 2 Doses | 3 Doses | Symptomatic | SARS-CoV-2 PCR Positive |
| All tests, no. (row %) | 7422 (100) | 321 (4) | 4366 (59) | 909 (12) | 1617 (22) | 209 (3) | 1361 (18) | 506 (7) |
| Female sex | 6020 (81) | 299 (93) | 3493 (80) | 717 (79) | 1343 (83) | 168 (80) | 1070 (81) | 388 (79) |
| Location | ||||||||
| HUP | 4563 (61) | 129 (40) | 3055 (70) | 636 (70) | 659 (41) | 84 (40) | 825 (63) | 300 (61) |
| Presbyterian | 540 (7) | 19 (6) | 183 (4) | 49 (5) | 262 (16) | 27 (13) | 77 (6) | 31 (6) |
| PAH | 850 (11) | 37 (12) | 237 (5) | 40 (4) | 464 (29) | 72 (34) | 102 (8) | 54 (11) |
| Princeton | 780 (11) | 96 (30) | 484 (11) | 100 (11) | 90 (6) | 10 (5) | 74 (6) | 41 (8) |
| Chester | 689 (9) | 40 (12) | 407 (9) | 84 (9) | 142 (9) | 16 (8) | 240 (18) | 63 (13) |
| Age, y | ||||||||
| 18–30 | 1714 (23) | 93 (29) | 1084 (25) | 187 (21) | 321 (20) | 29 (14) | 358 (26) | 137 (27) |
| 31–40 | 2685 (36) | 124 (39) | 1633 (37) | 355 (39) | 516 (32) | 57 (27) | 490 (36) | 170 (34) |
| 41–50 | 1208 (16) | 55 (17) | 692 (16) | 129 (14) | 297 (18) | 35 (17) | 242 (18) | 91 (18) |
| 51–60 | 1143 (15) | 30 (9) | 612 (14) | 144 (16) | 317 (20) | 40 (19) | 187 (14) | 72 (14) |
| >60 | 672 (9) | 19 (6) | 345 (8) | 94 (10) | 166 (10) | 48 (23) | 84 (6) | 36 (7) |
| Race/ethnicity | ||||||||
| White | 4736 (64) | 173 (54) | 2810 (64) | 639 (70) | 971 (60) | 143 (68) | 906 (67) | 341 (67) |
| Black | 1493 (20) | 120 (37) | 836 (19) | 95 (10) | 406 (25) | 36 (17) | 230 (17) | 104 (21) |
| Asian | 611 (8) | 4 (1) | 372 (9) | 104 (11) | 112 (7) | 19 (9) | 111 (8) | 25 (5) |
| Other | 522 (7) | 22 (7) | 316 (7) | 67 (7) | 106 (7) | 11 (5) | 97 (7) | 32 (6) |
| Latinx | 60 (1) | 2 (1) | 32 (1) | 4 (0) | 22 (1) | 0 (0) | 17 (1) | 4 (1) |
| Clinical job role | 4728 (64) | 201 (65) | 2855 (66) | 609 (67) | 942 (59) | 121 (59) | 860 (64) | 318 (63) |
| Time since dose 2 or 3, wk | ||||||||
| <8 | … | … | 152 (3) | 711 (78) | 45 (3) | 162 (87) | … | … |
| 8–12 | … | … | 131 (3) | 161 (18) | 21 (1) | 10 (5) | … | … |
| 12–16 | … | … | 132 (3) | 132 (3) | 38 (2) | 2 (1) | … | … |
| 16–20 | … | … | 130 (3) | 130 (3) | 51 (3) | 0 (0) | … | … |
| 20–24 | … | … | 171 (4) | 171 (4) | 114 (7) | 1 (1) | … | … |
| >24 | … | … | 3650 (84) | 30 (3) | 1348 (83) | 11 (6) | … | … |
Abbreviations: Chester, Chester County Hospital; HUP, Hospital of the University of Pennsylvania; PAH, Pennsylvania Hospital; PCR, polymerase chain reaction; Presbyterian, Penn Presbyterian Medical Center; Princeton, Princeton Health; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Data represent no. (column %) of study participants unless otherwise specified.